Oncopeptides AB (publ) – announced that the FDA, has approved Pepaxto (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the treatment of adult patients with… read more.
The centre is part of the German Federal Institute for Risk Assessment (BfR). With the help of microscopy and artificial intelligence, the “E-Morph” test reliably identifies substances that… read more.
Merck announced the company is voluntarily withdrawing the U.S. indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression… read more.
AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was… read more.
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of an expanded… read more.
Bristol Myers Squibb announced that the European Commission (EC) has granted full Marketing Authorization for Inrebic (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in… read more.
Interview and article by Christine Clark. Delayed diagnoses and more patients with advanced cancers were consequences of the coronavirus pandemic, according to Dr Erin Schenk, Assistant Professor, Thoracic… read more.
Interview and article by Christine Clark. Modern lung cancer treatment has changed the outlook for lung cancer patients considerably and interesting trial results are expected this year, according… read more.
Interview and article by Christine Clark IMI interviewed Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado to find out about key trial results in lung cancer… read more.
Article written by Bruce Sylvester Investigators from the QUAZAR trial report that treatment with oral azacytidine (CC-486), significantly improves survival in older patients, over age of 55, with… read more.
Genetic testing can uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, manage cancer in loved ones and push the boundaries of precision medicine.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
